Replimune (REPL) Income from Continuing Operations (2017 - 2026)
Replimune (REPL) reported Income from Continuing Operations of 73168000.0 for Q1 2026, up 1.34% on a YoY basis from 72200292.94 in Q1 2025, and down 3.14% sequentially from 70941000.0 in Q4 2025.
Replimune (REPL) Income from Continuing Operations (2017 - 2026) Analysis & Trends
Replimune (REPL) has 10 years of Income from Continuing Operations data on file, last reported at 73168000.0 in Q1 2026.
- For the quarter ending Q1 2026, Income from Continuing Operations rose 1.34% year-over-year to 73168000.0; the trailing twelve-month figure through Mar 2026 stood at 395750000.0 (down 60.01% YoY), and the FY2026 full-year result was 313891000.0, down 26.91% from the prior year.
- Income from Continuing Operations slipped to 73168000.0 in Q1 2026, from 70941000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 31615000.0 in Q1 2022 to a low of 128724000.0 in Q2 2025.
- A 5-year average of 62634352.94 and a median of 53772000.0 in 2024 frame the typical range for Income from Continuing Operations.
- Across the five-year window, Income from Continuing Operations soared 51.52% in 2022 and slumped 139.39% in 2025, its largest moves.
- Tracing REPL's Income from Continuing Operations over 5 years: stood at 39690000.0 in 2022, then slipped by 28.8% to 51120000.0 in 2023, then decreased by 29.77% to 66340000.0 in 2024, then decreased by 6.94% to 70941000.0 in 2025, then dropped by 3.14% to 73168000.0 in 2026.
- Business Quant data shows REPL's Income from Continuing Operations at 73168000.0 in Q1 2026, 70941000.0 in Q4 2025, and 122917000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 227.36 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.68 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | Replimune | 970.73 Mn | 970.73 Mn | - | -73.17 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -73.17 Mn |
| Dec 31, 2025 | -70.94 Mn |
| Sep 30, 2025 | -122.92 Mn |
| Jun 30, 2025 | -128.72 Mn |
| Mar 31, 2025 | -74.16 Mn |
| Dec 31, 2024 | -66.34 Mn |
| Sep 30, 2024 | -53.06 Mn |
| Jun 30, 2024 | -53.77 Mn |
| Mar 31, 2024 | -55.08 Mn |
| Dec 31, 2023 | -51.12 Mn |
| Sep 30, 2023 | -60.04 Mn |
| Jun 30, 2023 | -49.56 Mn |
| Mar 31, 2023 | -49.25 Mn |
| Dec 31, 2022 | -39.69 Mn |
| Sep 30, 2022 | -43.10 Mn |
| Jun 30, 2022 | -42.25 Mn |
| Mar 31, 2022 | -31.62 Mn |
| Dec 31, 2021 | -81.86 Mn |
| Sep 30, 2021 | -82.05 Mn |
| Jun 30, 2021 | -80.79 Mn |